H . Segment Information Our business consists of two segments for financial reporting purposes. The two segments are identified as (i) private-label contract manufacturing, which primarily relates to the provision of private-label contract manufacturing services to companies that market and distribute nutritional supplements and other health care products, and (ii) patent and trademark licensing, which primarily includes direct raw material sales and royalty income from our license and supply agreements associated with the sale and use of beta-alanine under our CarnoSyn and SR CarnoSyn trade names. We evaluate performance of these segments based on a number of factors. The primary performance measures for each segment are net sales and income or loss from operations before the allocation of certain corporate level expenses. Operating income or loss for each segment does not include corporate general and administrative expenses, interest expense and other miscellaneous income and expense items. Corporate general and administrative expenses include, but are not limited to human resources, corporate legal, finance, information technology, and other corporate level related expenses, which are not allocated to any segment. Transfers of raw materials between segments are recorded at cost. The accounting policies of our segments are the same as those described in the summary of significant accounting policies in Note A. above and in the consolidated financial statements included in our 2020 Annual Report. Our operating results by business segment were as follows (in thousands): Three Months Ended September 30, 20 20 2019 Net Sales Private-label contract manufacturing $ 37,047 $ 26,009 Patent and trademark licensing 2,679 3,186 Total Net Sales $ 39,726 $ 29,195 Three Months Ended September 30, 2020 2019 Income (Loss) from Operations Private-label contract manufacturing $ 3,424 $ 1,613 Patent and trademark licensing 670 213 Income from operations of reportable segments 4,094 1,826 Corporate expenses not allocated to segments (2,009 ) (1,881 ) Total Income (Loss) from Operations $ 2,085 $ (55 ) September 30, 2020 June 30, 2020 Total Assets Private-label contract manufacturing $ 107,730 $ 100,094 Patent and trademark licensing 20,826 20,109 $ 128,556 $ 120,203 Our private-label contract manufacturing products are sold both in the U.S. and in markets outside the U.S., including Europe, Canada, Australia, New Zealand, and Asia. Our primary markets outside the U.S. are Europe and Asia. Our patent and trademark licensing activities are primarily based in the U.S. Net sales by geographic region, based on the customers' location, were as follows (in thousands): Three Months Ended September 30, 2020 2019 United States $ 19,785 $ 18,185 Markets outside of the United States 19,941 11,010 Total $ 39,726 $ 29,195 Products manufactured by our Swiss subsidiary ("NAIE") accounted for 86% of net sales in markets outside the U.S. for the three months ended September 30, 2020. Products manufactured by NAIE accounted for 89% of net sales in markets outside the U.S. for the three months ended September 30, 2019. No products manufactured by NAIE were sold in U.S. markets during the three month periods ended September 30, 2020 and 2019. Long-lived assets by geographic region, based on the location of the company or subsidiary at which they were located or made, were as follows (in thousands): September 30, 20 20 June 30, 20 20 United States $ 21,272 $ 21,769 Europe 18,463 18,108 Total Long-Lived Assets $ 39,735 $ 39,877 Total assets by geographic region, based on the location of the company or subsidiary at which they were located or made, were as follows (in thousands): September 30, 20 20 June 30, 20 20 United States $ 72,768 $ 66,489 Europe 55,788 53,714 Total Assets $ 128,556 $ 120,203 Capital expenditures by geographic region, based on the location of the company or subsidiary at which they were located or made, were as follows (in thousands): Three Months Ended September 30, 20 20 September 30, 201 9 United States $ 249 $ 406 Europe 1,230 712 Total Capital Expenditures $ 1,479 $ 1,118